In an attempt to further clarify the mechanism of the maintenance of the antihypertensive effect of 3-adrenoceptor antagonists, the effects of four antagonists with different ancillary properties (acebutolol, atenolol, pindolol, and propranolol) on systemic and renal hemodynamics, body fluid volumes, hormones, and lymphocyte 3-adrenoceptor density were studied in four groups of 10 hypertensive patients. The patients were observed for 3 weeks during active treatment and for 2 weeks after withdrawal of treatment. At the end of the 3-week treatment period, the four drugs had an equal antihypertensive effect (fall in mean arterial pressure, 10-13%). Although renin activity was suppressed (60-70%o) by all four drugs, changes in renin or pretreatment values of renin levels were not correlated with the fail in blood pressure. The drugs had no effect on plasma catecholamine concentrations or body fluid volumes. Despite similar antihypertensive effects among the four drugs, the changes in flow and resistance underlying the fall in blood pressure differed considerably. With pindolol, the fall in blood pressure was associated with a fall in vascular resistance (26+6%), whereas with propranolol, it was predominantly associated with a fall in cardiac output (11±7% 
to four groups of 10 patients with essential hypertension. 1 The antagonists were acebutolol, which is f31 selective with a moderate degree of partial agonist activity, atenolol, which is I13 selective, highly hydrophilic, and devoid of partial agonist activity, pindolol, which is nonselective with strong partial agonist activity, and propranolol, which is nonselective, highly lipophilic, and devoid of partial agonist activity. The experimental conditions in that study were rigidly standardized by restricting the patients to bed for 36 hours. The results led us to conclude that despite the different ancillary properties the four drugs exerted a similar antihypertensive effect, which was mediated by a vasodilator mechanism. Autoregulatory adjustment of the vasculature to changes in tissue perfusion or suppression of renin activity were found to be unlikely candidates to explain this vasodilator mechanism.
The present study is an extension of our initial report. The patients were observed for 3 weeks during active treatment and for 2 weeks after withdrawal of treatment. In this period, repeated measurements of cardiac output, renal perfusion, plasma catecholamine levels, renin activity, aldosterone levels, body fluid volumes, lymphocyte f,-adrenoceptors, and cardiac chronotropic responsiveness to isoproterenol were performed. In this way, by searching for similarities, dissimilarities, and eventually common denominators of the antihypertensive effect of the four different ,3-adrenoceptor antagonists, we hoped to gain additional information on the mechanism that maintains the antihypertensive effect during prolonged treatment.
Methods

Patients
Forty male patients (age range, 27-64 years; mean age, 46 years) with mild-to-moderate essential hypertension were studied. They were recruited from the outpatient hypertension clinic if their untreated sitting diastolic blood pressure was over 95 mm Hg (phase V of Korotkoff sounds) at three separate occasions. Routine clinical and laboratory evaluation did not reveal causes of their hypertension. A history of or clinical signs of coronary or valvular heart disease, congestive heart failure, cerebrovascular disease, or chronic obstructive lung disease were all negative. After the purpose and the procedures of the study had been explained, all patients gave their consent to participate. The protocol was approved by the local hospital ethical review committee.
Study Protocol
This was a single-blind, placebo-controlled study, and it lasted for 7 weeks. Antihypertensive and other types of medication, if any, were discontinued at least 3 weeks before the study. A moderate dietary salt restriction was advised (approximately 8 g/day NaCl). After the washout period, placebo was given for 2 weeks. The placebo tablets were matched with the active medication with regard to the appearance and the number of tablets taken each day. After the placebo period, the patients were treated with one of the four ,B-adrenoceptor antagonists for 3 weeks. During the first week of the active treatment, propranolol was given 40 mg three times daily, atenolol 50 mg once daily, acebutolol 200 mg twice daily, and pindolol 5 mg twice daily. Depending on the blood pressure response, the dose of the 3-adrenoceptor antagonists was doubled during each of the two subsequent weeks until blood pressures below 140/90 mm Hg were obtained. After 3 weeks of active treatment, the patient was given placebo again for 2 weeks.
During the entire study, patients were seen at weekly intervals in the outpatient clinic. At each visit, supine blood pressure and heart rate were measured for 1 hour. Cardiac output, glomerular filtration rate, effective renal plasma flow, and the plasma and extracellular volumes were measured at the end of the initial placebo period and after 3 weeks of active treatment. Blood was collected while the patients were in the supine position for determination of plasma levels of catecholamines, renin levels, and aldosterone levels, two times, one week apart, during the placebo period and at the end of the active treatment period. The density of ,B-adrenoceptors on lymphocyte membranes (Bm,x) was determined twice during the placebo period, 24 hours after the first dose of the f3-adrenoceptor antagonists, at the end of the second and third weeks of active treatment, and at the end of the first and second weeks after withdrawal of active treatment. Blood was always sampled at the end of the dosing interval of the respective drugs. The chronotropic responsiveness of cardiac ,B-adrenoceptors to isoproterenol (CD25) was assessed at the end of the initial placebo period and 1 week after withdrawal of the /8-adrenoceptor antagonists.
Hemodynamic Measurements
Supine blood pressure and heart rate were measured at 5-minute intervals for 1 FRG) . Baseline values of heart rate were obtained during a continuous infusion of saline at a flow rate of 22 ml/hr for 20 minutes. The infusion was then switched to isoproterenol, 3.5, 7, 14, 35, and 70 ng/kg/min. The infusion rate was increased every 10 minutes until a rise in heart rate of at least 25 beats/min was obtained. The rise in heart rate during each dose step was used for constructing a log dose-response curve. From this curve, the dose of isoproterenol required to increase the heart rate by 25 beats/min (CD25, ng/kg/min) was calculated. /-Adrenergic Receptor Density on Lymphocyte Membranes
Preparation of Lymphocytes. Blood samples for the preparation of lymphocyte membranes were always taken after 1 hour of supine rest at the end of the dosing interval before isoproterenol was given and before isotopes were used for hemodynamic studies.
Lymphocytes were isolated from fresh heparinized blood by a modification of the technique described by Boyum.8 Fresh heparinized blood (50 ml) was diluted with an equal volume of 0.154 M NaCl and was divided into four equal fractions. An aliquot (15 ml) of Isolymph (Gallard-Schlesinger Chemical Manufacturing, Carle Place, New York) was carefully layered under 25 ml diluted blood with an 18-gauge spinal tap needle. Tubes were centrifuged at 400g for 40 minutes at 200 C. After careful removal of the plasma, the lymphocyte band (at least 90% small lymphocytes, <8% monocytes, <2% polymorphonuclear leukocytes) was harvested by vacuum aspiration. Lymphocytes prepared from 50 ml whole blood were subdivided into four equal fractions, each of which was diluted with 20 ml 20 mM Tris-isosaline (pH 7.5, 200 C). After centrifugation at 400g for 40 minutes at 200 C, the supernatant was carefully removed by vacuum suction, and the pellet was gently resuspended in 20 ml solution I (anhydrous D-glucose 1.0 g/l, CaCl2 0.0056 g/l, MgCl26H2O 0.4249 g/l, KCl 0.4026 g/l, and Tris 17.565 g/l, pH 7.6) with a rubber policeman. Homogenates were centrifuged at 20,000g for 10 minutes at 40 C, and supernatants were discarded. Pellets resuspended in 10 ml ice-cold distilled H2O were then homogenized (Polytron, Kinematica, Kriens/ Luzern, Switzerland, setting 6 for 10 seconds), and samples were centrifuged at 20,000g for 10 minutes at 40 C. The supernatants were discarded, and the four pellets were resuspended in two tubes containing 4 ml solution 1 (4°C) with a Polytron (setting 5.5 for 10 seconds). The membranes originating from 50 ml whole blood were stored at -70°C until assay.
f-Adrenergic Receptor Binding Assay (-)-Pindolol was iodinated with 125I, and 1251_ pindolol was purified to theoretical specific activity (2.2 Ci/,mol) as described previously.9 Samples were thawed and rehomogenized (Polytron, at setting 6 for 8 seconds). Aliquots (100 ,ul) of each homogenate containing 15-25 ,ug protein were incubated with the indicated concentrations of 1251 
Results
Systemic Hemodynamics
With regard to the clinical characteristics of the four groups of patients at the end of the washout period, there were no significant differences ( Table 1) .
The changes in blood pressure and heart rate during administration and after withdrawal of the four 18-adrenoceptor blocking agents were very similar ( Figure 1 tion of active treatment did not differ from values observed during the initial placebo period. Heart rate decreased during administration of acebutolol, atenolol, and propranolol. In contrast, no change in heart rate occurred with pindolol (Table 2) . After 3 weeks of treatment, the heart rate during acebutolol (64±2 beats/min) was slightly higher (p<0.05) than the heart rates during atenolol (58±3 beats/min) or propranolol (57 +2 beats/min). After withdrawal from active treatment, heart rates did not differ from the values of the initial placebo period in any of the four Bmaxincreased by 51±17% (p<0.01) after 3 weeks of treatment with propranolol ( Figure 3) . By (Figure 2) . Conversely, during treatment with pindolol, which is a nonselective antagonist with a relatively high degree of partial agonist activity, the antihypertensive effect was entirely due to a fall in vascular resistance. At variance with some previous studies, the antihypertensive effect of the /31-selective antagonist atenolol was not associated with a decrease in cardiac output.'1819 The alterations in systemic hemodynamics caused by acebutolol did not differ from those of atenolol. This reflects the relatively low degree of partial agonist activity of acebutolol.
In comparing the present data with those of previous studies, the fall in cardiac output, if present at all, during administration of ,3-adrenoceptor antagonists devoid of partial agonist activity was relatively small. Moreover, after pindolol with its pronounced partial agonist activity, cardiac output even moderately increased. Hemodynamic measurements in this study were performed after 2 hours of supine rest. The patients were therefore in a baseline state, and as reflected by their low heart rates, cardiac sympathetic drive was low. This may explain why on average relatively little cardiodepression was exerted by the ,3-adrenoceptor antagonists and why the cardiostimulant action of pindolol could be demonstrated. The hemodynamic data after 3 weeks of treatment with equipotent doses of the four f8-adrenoceptor agonists are in close agreement with the hemodynamic profiles of these drugs during the onset of their blood pressure-lowering effect within the first 24 hours after their administration.' Analy- sis of the hemodynamic interrelations during onset of the antihypertensive effect of these drugs led us to conclude that after an initial period of cardiodepression and reflex-vasoconstriction, acebutolol, atenolol, and propranolol lowered blood pressure by a decrease in vascular resistance that was accompanied by a return of cardiac output, heart rate, and stroke volume to baseline. With pindolol, the initial cardiodepression and reflex vasoconstriction were absent. The fall in blood pressure on this drug was through a reduction in vascular resistance, whereas cardiac output was raised. Under the strict basal conditions of our study and despite cardiac /3-blockade, we suggested that withdrawal of vagal tone, afterload reduction, and an increase in venous return to the heart were the factors most likely to be involved in the adaptive changes of cardiac output.
Renal Function
Although deterioration of renal function during administration of,-adrenoceptor antagonists has sporadically been reported,20'21 the adverse effects of these drugs on renal function usually appear to be small and reversible.22 '23 This could be confirmed in the present study: glomerular filtration rate did not change significantly after any of the four drugs, although it tended to decrease on propranolol and to increase on pindolol.
Reduction in cardiac output, suppression of renin, blockade of vasodilating ,82-receptors in the kidney, and alterations in plasma volume are all possible factors, which may adversely affect renal perfusion during /3-adrenoceptor blockade.22 '23 In the present study, renin was suppressed to a similar degree, and plasma volume was unchanged by any of the four drugs, whereas changes in renal perfusion occurred in parallel with the changes in cardiac output. In our view, these findings suggest that the changes in renal perfusion, which may occur during /3-adrenoceptor antagonism, are at least in part a consequence of the changes induced by 83-adrenoceptor antagonists in systemic hemodynamics.
Plasma Catecholamine Concentrations
The literature is not unanimous concerning the effects of ,B-adrenoceptor antagonism on plasma levels of norepinephrine and epinephrine. Increments, decrements, and no changes in plasma catecholamine levels during administration of ,Breceptor antagonists have all been reported. 24 The interpretation of plasma levels of norepinephrine during administration of /3-blockers is complicated by the fact that these drugs may affect not only the release of this neurotransmitter into plasma but also its clearance rate from plasma. Norepinephrine is mainly cleared from the circulation by the liver and the lung.25 A decreased flow through these organs, concomitant with a fall in cardiac output, impairs the clearance of norepinephrine and as a consequence may result in increased plasma levels of the neurotransmitter.26 28 In the present study, this may explain why norepinephrine tended to increase with propranolol, but not with the other three drugs, because cardiac output tended to decrease only on this drug. Increments in plasma norepinephrine concentration during /3-adrenoceptor antagonism therefore do not necessarily imply that sympathetic tone is increased. In other words, reduced sympathetic activity and diminished release of norepinephrine can easily be masked by this phenomenon. The absence of a rise in norepinephrine levels during the "vasodilator" and antihypertensive action of ,3-adrenoceptor antagonists can be considered inappropriate and could therefore suggest interfer- The renin suppressant effect of /3-adrenoceptor blocking agents has been linked to the antihypertensive mechanism of these drugs.36 Indeed, evidence indicates that in patients with high-renin forms of hypertension renin suppression contributes to the blood pressure-lowering effect of these drugs, but this renin suppressant effect probably does not also contribute to the blood pressurelowering effect of these drugs in most patients with normal or low-renin forms of hypertension.37,38 If, in the present study, the fall in blood pressure was due to renin suppression, a relation between pretreatment values of renin and the antihypertensive effect has been expected; however, such a correlation was not found. Furthermore, in our short-term study, renin was already near maximum suppression 2 hours after administration of acebutolol, atenolol, and propranolol, whereas blood pressure had not fallen at all.' Moreover, in that study, pindolol exerted its maximal antihypertensive effect 24 hours after administration, whereas renin was no longer reduced at that time.
Lymphocyte [B-Adrenoceptor Density and
Isoproterenol Sensitivity
Studies in humans and in vitro studies indicate that the changes in the density and responsiveness of /3-adrenoceptors on lymphocytes can be used as a model to study the alterations of these receptors in less accessible tissues such as the heart and the data. First, during placebo, an inverse correlation between the density of lymphocyte /3-adrenoceptors and the chronotropic responsiveness of the heart to isoproterenol was established. An inverse correlation between these two parameters has also been reported by Fraser et al. 4 ' However, in their study, this correlation was found after repeated measurements of these parameters in the same group of normotensive subjects under different sodium balances. Second, and more important, the downregulation of lymphocyte /3-adrenoceptors 1 week after withdrawal of pindolol coincided with a decrease in the cardiac chronotropic responsiveness to isoproterenol, whereas the up-regulation of lymphocyte /3-adrenoceptors 1 week after withdrawal of propranolol coincided with an increased cardiac chronotropic responsiveness.
Lymphocyte To some extent, our study supports these cyte ,3-adrenoceptors may also be helpful for determining the degree of partial agonist activity or receptor selectivity of ,B-adrenoceptor antagonists.
Conclusions
The j3-adrenoceptor antagonists propranolol, pindolol, acebutolol, and atenolol appear to exert, with appropriate doses, equal antihypertensive effects. Despite this similarity among the four drugs in antihypertensive effect, the drugs have dissimilar effects on cardiac output, renal blood flow, and lymphocyte 3-adrenoceptors. In contrast, their effects on catecholamine concentrations, the reninangiotensin-aldosterone system, and body fluid volumes are not different. Changes in cardiac output, the circulating blood volume, or angiotensinmediated vasoconstriction are unlikely to be the crucial mechanism for the antihypertensive effect of /3-adrenoceptor antagonists. By exclusion of the above possibilities, we suggest that interference with sympathetic vasoconstrictor nerve activity through blockade of either central or peripheral prejunctional f3-adrenoceptors could be an alternate explanation of antihypertensive effect of these drugs. The absence of a fall in plasma norepinephrine levels does not necessarily contradict such a contention because concomitant changes in the clearance of plasma norepinephrine have to be taken into account.
